Skip to main content

Table 1 Demographic data

From: The impact of intravenous iron supplementation in elderly patients undergoing major surgery

  

A−

(n = 1,364)

A−, ID+, T+

(n = 36)

A+

(n = 576)

A+, ID+, T+

(n = 215)

Age

73.6 (± 5.8)

74 (± 5.4)

75.1 (± 6.2)

76.3 (± 6.3)

Gender (female)

28.4%

(n = 388)

54.1%

(n = 20)

25.5%

(n = 150)

42.6%

(n = 95)

BMI

27.1 (± 4.8)

24.6 (± 4.7)

26.4 (± 5.1)

26.5 (± 4.6)

ASA

I-II

17.9%

(n = 244)

21.6%

(n = 8)

6.8%

(n = 39)

6.9%

(n = 15)

 

III-IV

81.9%

(n = 1,117)

78.4%

(n = 28)

92.3%

(n = 532)

92.2%

(n = 198)

 

V

0.2%

(n = 3)

0%

(n = 0)

0.9%

(n = 5)

0.9%

(n = 2)

Surgical discipline

    
 

Cardiac thoracic surgery

52.3%

(n = 713)

37.8%

(n = 13)

44.7%

(n = 258)

36.3%

(n = 78)

 

Urology

17.8%

(n = 243)

13.5%

(n = 5)

8.0%

(n = 46)

7.2%

(n = 16)

 

Vascular surgery

13.3%

(n = 181)

13.5%

(n = 5)

20.7%

(n = 119)

25.1%

(n = 54)

 

Visceral surgery

11.7%

(n = 160)

24.3%

(n = 9)

21.9%

(n = 126)

27.8%

(n = 60)

 

Maxillofacial surgery

4.4%

(n = 60)

10.8%

(n = 4)

2.0%

(n = 12)

3.1%

(n = 6)

 

Orthopaedic/trauma surgery

0.4%

(n = 6)

0%

(n = 0)

2.4%

(n = 14)

0.4%

(n = 1)

 

Gynaecology

0.1%

(n = 1)

0%

(n = 0)

0.2%

(n = 1)

0%

(n = 0)

Preoperative Hb (g/dl) a

14.2 (± 1.1)

13.2 (± 0.9)

11.1 (± 1.3)

10.6 (± 1.5)

 

14.1(13.4; 14.9)

13.2 (12.5; 13.6)

11.3 (10.4; 12.2)

11 (9.6; 11.8)

 

female

13.4 (± 1)

12.9 (± 0.8)

10.6 (± 1.1)

10.5 (± 1.4)

  

13.3 (12.7; 14)

12.7 (12.3; 13.6)

10.8 (10; 11.4)

10.8 (9.6; 11.5)

 

male

14.5 (± 1)

13.6 (± 0.8)

11.3 (± 1.3)

10.7 (± 1.5)

  

14.4 (13.7; 15.1)

13.4 (13; 13.7)

11.5 (10.6; 12.4)

11.1 (9.6; 12)

  1. aHb haemoglobin, first Hb level in the course of treatment